CRN Responds to JAMA Fish Oil Study

-Association Reinforces the Importance of DHA Before, During and After Pregnancy-

WASHINGTON, Oct. 19 /PRNewswire-USNewswire/ -- In response to a study regarding fish oil use during pregnancy published in the October 19 issue of the Journal of the American Medical Association (JAMA), the Council for Responsible Nutrition (CRN), the leading trade association for the dietary supplement industry, reminds pregnant and lactating women of the undisputed importance of consuming the recommended amounts of docosahexaenoic acid (DHA) throughout pregnancy. This can be done by eating two servings of fatty fish, such as sardines or anchovies, per week, or taking fish oil supplements (containing 200-300 mg/DHA, according to the Institute of Medicine) daily. While the benefits of DHA for a healthy pregnancy are well-established, more research is necessary to determine the effect of DHA on incidence of post-partum depression or neurocognitive development of infants.

"A large body of scientific evidence has established a strong relationship between the DHA status of mothers and infants and a variety of important pregnancy-related outcomes, including infant development," said Duffy MacKay, N.D., vice president, scientific & regulatory affairs, CRN.  "Unfortunately in this trial, we have no idea of the DHA status of the mothers at the beginning of pregnancy or when they were evaluated for depression. Further we have no idea of the DHA status of the infants at 18 months when they were evaluated for neurocognitive outcomes. Without measurements of DHA status, it is difficult to draw conclusions from the study and certainly should not provide definitive advice to consumers."

There are many established variables that would impact individual DHA status for the mothers and children of both the supplemented and control group in this study, including differences in the ability to synthesize DHA from other fatty acids, the rate of maternal to fetal transfer of DHA, the status of other nutrients required to synthesize DHA, as well as other dietary sources of DHA not controlled for.

Dr. MacKay continued that the timeliness of the dosing may have had an impact.  "Supplementation occurred from mid-term to delivery—we know that maternal DHA status returns to below pre-pregnancy levels within a few weeks from delivery. A mother in the treatment group who started the trial with low DHA status would have returned to pre-pregnancy status by the time she was evaluated for depression at six weeks and six months post delivery. We may have seen different results if these women took fish oil consistently leading up to, during and after pregnancy, or if we were able to stratify the results based on DHA status."

This applies to the findings for the infants, as well, as there is no information about what they were given in the eighteen month period following birth—some infants in the control group may have received DHA through breast milk if the mother was eating fish or taking fish oil supplements, or through DHA-enriched formula.

"Essentially, DHA status needs to be adequate throughout pregnancy for women and their infants to receive the many established benefits," continued Dr. MacKay.  "We must also remember that both depression and childhood development are impacted by many different variables and maintaining good nutrition is just one important preventive step mothers can take to achieve the best outcomes. Taking fish oil has so many benefits; although this study did not prove that DHA dramatically impacted these complicated issues under these specific conditions, it's still widely known to be important for pregnant women and their offspring."

The DHA to Optimize Mother Infant Outcome (DOMInO) trial was conducted in five Australian maternity hospitals of 2,399 pregnant women who were less than 21 weeks' gestation to determine if taking fish oil provided 1) reduced risk of depressive symptoms in the postnatal period, and 2) improved developmental outcomes in the offspring.  

Secondary study findings showed that the women supplemented with DHA had lower incidence of preterm birth and lower incidence of low birth weight offspring, which is associated with a variety of positive long-term outcomes, including better cognitive development.  Aside from its heart benefits, fish oil is also important for mothers-to-be as it is known to reduce inflammation and promote brain, skin, bone and eye health.  

"As the accompanying editorial acknowledges, taking fish oil can contribute to an overall healthy pregnancy.  We encourage pregnant and lactating women, and all women of childbearing age to talk with their doctors and make sure they are receiving adequate amounts of DHA," said Dr. MacKay.  "Additionally, these women should take 400 mcg of folic acid to help prevent neural tube birth defects.  There are many things women can do to help optimize their health and wellness during pregnancy—and at the end of the day all of this translates into better health for their baby."

The Council for Responsible Nutrition (CRN), founded in 1973, is a Washington, D.C.-based trade association representing dietary supplement manufacturers and ingredient suppliers.  In addition to complying with a host of federal and state regulations governing dietary supplements in the areas of manufacturing, marketing, quality control and safety, our 70+ manufacturer and supplier members also agree to adhere to additional voluntary guidelines as well as CRN's Code of Ethics. Visit www.crnusa.org.  

SOURCE Council for Responsible Nutrition